

Investing to Protect the United States and the World Against AR

Antimicrobial resistance (AR), when germs do not respond to the drugs designed to kill them, threatens to return us to the time when simple infections were often fatal. CDC is committed to protecting people and the future of the healthcare, veterinary, and agriculture industries from the threat of antimicrobial resistance.

The AR Investment Map showcases CDC's critical activities in the U.S. and abroad to combat AR with investments in laboratory and epidemiological expertise and public health innovation. CDC supports most of these activities through its AR Solutions Initiative, while also leveraging investments from successful programs across the agency for maximum efficiency. The map also includes activities supported by emergency supplemental funding provided to CDC, highlighted in a fact sheet.

Since 2016, CDC has supported comprehensive AR work in the U.S. and leveraged lessons learned for local solutions abroad.

- Projects in the U.S. and more than 60 countries abroad.
- More than \$815 million to 59 state and local health departments.
- Supporting 500+ local AR experts
- CDC's AR Lab Network sent 29,000 alerts about unusual antimicrobial resistance that required a public health response.

DETECTION, RESPONSE, & CONTAINMENT

- **Laboratory & Diagnostics:** Gold-standard lab capacity offered to all state and regional labs through CDC's AR Laboratory Network.
- **Epidemiology Capacity for Response:** Increased capacity in state, territorial, and local health departments for rapid detection and faster response to outbreaks and emerging resistance related to healthcare-associated infections, foodborne bacteria, and gonorrhea—to contain and control spread.

PREVENTION

- **Surveillance & Science:** More effective tracking and prevention of healthcare-associated infections, foodborne illness, and gonorrhea (a sexually transmitted infection).
- **Improved Antibiotic & Antifungal Use:** With partners, improve antibiotic and antifungal use to ensure these drugs work to protect patients from life-threatening infections or sepsis.

INNOVATION

- **Insights for Practice:** With academic and healthcare partners, CDC is investing in innovations and collaborating with investigators to identify and implement new ways to prevent antimicrobial-resistant infections and their spread.
- **Research & Development:** Sharing isolates that inform development of new drugs and diagnostics and making CDC's sequencing data from AR pathogens public to spur innovation in industry.

These investments work toward meeting national goals to prevent antimicrobial-resistant infections as outlined in the [National Action Plan for Combating Antibiotic-Resistant Bacteria](#).

See CDC's AR investments by state at ARinvestments.cdc.gov.

The AR Investment Map includes data from CDC's largest funding categories for AR. It represents extramural funding that supports AR activities from multiple funding lines in CDC's annual appropriations. Some work received full or partial funding from one-time supplemental appropriations. See the fiscal year 2023 AR Investment Map Supplemental Funding Fact Sheet for more information.

AR: antimicrobial resistance
COVID-19: coronavirus disease 2019
HAI: healthcare-associated infection
IPC: infection prevention and control

NHSN: National Healthcare Safety Network
STD: sexually transmitted disease
STI: sexually transmitted infection